This randomized, double-blind, placebo-controlled, 3-part study will assess the safety,
tolerability, and pharmacokinetics of orally administered ALS-002200 in healthy volunteers
(HV) and subjects with chronic hepatitis C (CHC) genotype 1 infection.
Part 1 will assess single ascending dosing pharmacokinetics and safety in HV. Part 2 will
assess food effects on pharmacokinetics in HV. Part 3 will assess multiple ascending dosing
pharmacokinetics and safety in subjects with CHC genotype 1 infection.